NKGen Biotech

NKGen Biotech (OTC:NKGN) activates 3 new U.S. sites for Phase 2 troculeucel Alzheimer's study, expanding patient access & supporting enrollment. Learn more: bit.ly/4dkqNmI $NKGN

NKGen Biotech (OTC: NKGN) to present at the 8th Annual Neuroimmunology Drug Development Summit in Boston. CEO Dr. Paul Y. Song will highlight troculeucel’s potential in Alzheimer’s & FTD, including new mechanistic & early clinical insights. $NKGN bit.ly/4spEwgf

NKGen Biotech (OTC: NKGN) reported combined analysis of Ph 1 Alzheimer’s data at AD/PD™ 2026: 100% stable/improved, 50% improved to milder function, with dose-response, durability & GFAP biomarker support for ongoing Phase 2. $NKGN bit.ly/4bIH6HK

NKGen Biotech (OTC:NKGN) will present integrated Phase 1 analyses of troculeucel in Alzheimer’s disease at AD/PD™ 2026: oral presentation on cognitive results & poster on biomarkers (plasma GFAP). $NKGN bit.ly/46OKoHX

NKGen Biotech, Inc. (OTC: NKGN) announced Bruce L. Miller, M.D., a globally recognized dementia expert, joined its Scientific Advisory Board. His expertise in neurodegenerative disease strengthens NKGen’s clinical programs and exploration of FTD. $NKGN bit.ly/4pTjeWW

NKGen Biotech (OTC: NKGN) today provided an update on recent Board appointments and the name change of its majority-owned affiliate, NKGen Biotech Korea Co., Ltd. See press release for full details. $NKGN bit.ly/4iDJXVB

November is National #AlzheimersAwareness Month. Over 6M Americans live with Alzheimer’s. At NKGen, we’re committed to advancing science and supporting those affected. Together, we work towards a brighter future built on the hope of new therapies. #Alzheimers #nkgenbiotech

NKGen Biotech (OTC: NKGN) has received questions about how our stock is displayed on some financial platforms. This is due to data reporting limitations associated with the OTC Expert Market. We’ve issued a press release to clarify: bit.ly/46UcxMR $NKGN

NKGen Biotech [OTC:NKGN] CEO, Dr. Paul Y. Song, will present at the World Congress of Neurology 2025 in Seoul, South Korea. Dr. Song will share the scientific rationale and latest clinical findings for troculeucel in Alzheimer’s disease. $NKGN bit.ly/4nVNvEF

Update: Due to typhoon-related disruptions in the Guangzhou region, Dr. Song will not be presenting at the 3rd China Great Bay Cell and Gene Therapy Forum this Friday as originally planned. Our thoughts are with everyone affected by the storm. $NKGN

NKGen [OTC:NKGN] CEO Paul Y. Song, M.D. to present on troculeucel for neurodegenerative diseases at the 3rd China Great Bay Forum (Sept 25-26, 2025). Note: date/time changed. Updated details here: bit.ly/3IrstxY $NKGN

NKGen Biotech [OTC: NKGN] has acquired a majority stake in former parent NKMax Co., Ltd., enhancing our manufacturing, IP, and global reach in NK cell therapeutics and supporting the development of our lead Alzheimer’s therapy and pipeline expansion. $NKGN bit.ly/46bDgnF

At NKGen Biotech, we are committed to developing treatments that bring hope to those affected by Alzheimer's. Together, we work to improve the lives of patients and their families, creating a brighter future for all. #nkgenbiotech #worldalzheimersmonth #nkcelltherapy #alzheimers

NKGen Biotech [OTC:NKGN] to present “Allogeneic Enhanced NK cells without Lymphodepletion in Solid Tumors” at the Immuno-Oncology Summit 2025, held in Philadelphia, August 13th. bit.ly/3J4h2fB  $NKGN

NKGen Biotech [OTC:NKGN] presented at #AAIC2025 on troculeucel’s proposed mechanism of action in Alzheimer’s disease. Data suggest troculeucel targets neuroinflammation, protein aggregation and can potentially slow disease progression. bit.ly/3INfQ02 $NKGN

On World Brain Day, we unite with global experts working diligently to improve brain health at every stage of life. #brainhealth

NKGen Biotech [OTC:NKGN] announces a poster presentation by CEO Dr. Paul Y. Song on the mechanism of action of troculeucel in patients with Alzheimer’s disease, Sunday, July 27th at the AAIC 2025 in Toronto, Canada. bit.ly/4m4Udqj $NKGN

NKGen Biotech [OTC:NKGN] receives expanded access protocol authorization from FDA for troculeucel to treat multiple neurodegenerative diseases. $NKGN bit.ly/3TSc5bZ

NKGen Biotech [OTC:NKGN] and HekaBio have entered a strategic partnership to advance development of troculeucel NK cell therapy in Japan. The collaboration supports regulatory and commercial efforts under Japan’s regenerative medicine framework. $NKGN bit.ly/4kOz6Yi

NKGen Biotech [OTC:NKGN] secures $2M in new funding from a strategic investor to support efforts to regain SEC filing compliance and listing standards. bit.ly/4eXK1xB $NKGN